Trials / Completed
CompletedNCT00890734
CYT003-QbG10 for Treatment of Allergic Asthma Bronchial
A Double-blind, Placebo-controlled Study to Assess Pharmacodynamic and Clinical Efficacy of CYT003-QbG10 in Patients With Persistent Allergic Asthma Bronchial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Cytos Biotechnology AG · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to test whether treatment with CYT003-QbG10 can improve asthma symptoms in patients with allergic bronchial asthma. The active treatment will be compared against placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CYT003-QbG10 | subcutaneous injection |
| DRUG | Placebo | subcutaneous injection |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2010-04-01
- Completion
- 2010-11-01
- First posted
- 2009-04-30
- Last updated
- 2012-02-13
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00890734. Inclusion in this directory is not an endorsement.